{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,20]],"date-time":"2026-09-20T12:45:48Z","timestamp":1789908348641,"version":"4.0.1"},"reference-count":29,"publisher":"Elsevier BV","issue":"11","license":[{"start":{"date-parts":[[2015,11,1]],"date-time":"2015-11-01T00:00:00Z","timestamp":1446336000000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2016,11,1]],"date-time":"2016-11-01T00:00:00Z","timestamp":1477958400000},"content-version":"vor","delay-in-days":366,"URL":"https:\/\/www.elsevier.com\/open-access\/userlicense\/1.0\/"}],"funder":[{"DOI":"10.13039\/501100000864","name":"British HIV Association","doi-asserted-by":"publisher","id":[{"id":"10.13039\/501100000864","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100000833","name":"Rosetrees Trust","doi-asserted-by":"publisher","id":[{"id":"10.13039\/501100000833","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["Clinical Microbiology and Infection"],"published-print":{"date-parts":[[2015,11]]},"DOI":"10.1016\/j.cmi.2015.07.017","type":"journal-article","created":{"date-parts":[[2015,7,30]],"date-time":"2015-07-30T04:51:00Z","timestamp":1438231860000},"page":"1033-1039","source":"Crossref","is-referenced-by-count":24,"title":["Detection of the NS3 Q80K polymorphism by Sanger and deep sequencing in hepatitis C virus genotype 1a strains in the UK"],"prefix":"10.1016","volume":"21","author":[{"given":"A.","family":"Beloukas","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"S.","family":"King","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"K.","family":"Childs","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"A.","family":"Papadimitropoulos","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"M.","family":"Hopkins","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"M.","family":"Atkins","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"K.","family":"Agarwal","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"M.","family":"Nelson","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"A.M.","family":"Geretti","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"key":"10.1016\/j.cmi.2015.07.017_bib1","doi-asserted-by":"crossref","first-page":"e39652","DOI":"10.1371\/journal.pone.0039652","article-title":"Hcv genotypes are differently prone to the development of resistance to linear and macrocyclic protease inhibitors","volume":"7","author":"Cento","year":"2012","journal-title":"PloS One"},{"key":"10.1016\/j.cmi.2015.07.017_bib2","doi-asserted-by":"crossref","first-page":"5288","DOI":"10.1128\/AAC.00777-10","article-title":"Susceptibility of treatment-naive hepatitis c virus (hcv) clinical isolates to hcv protease inhibitors","volume":"54","author":"Bae","year":"2010","journal-title":"Antimicrob Agents Chemother"},{"key":"10.1016\/j.cmi.2015.07.017_bib3","doi-asserted-by":"crossref","first-page":"1544","DOI":"10.1128\/JVI.02294-12","article-title":"Hepatitis c virus variants with decreased sensitivity to direct-acting antivirals (daas) were rarely observed in daa-naive patients prior to treatment","volume":"87","author":"Bartels","year":"2013","journal-title":"J Virol"},{"key":"10.1016\/j.cmi.2015.07.017_bib4","doi-asserted-by":"crossref","first-page":"698","DOI":"10.1128\/AAC.01976-13","article-title":"Baseline hepatitis c virus (hcv) ns3 polymorphisms and their impact on treatment response in clinical studies of the hcv ns3 protease inhibitor faldaprevir","volume":"58","author":"Berger","year":"2014","journal-title":"Antimicrob Agents Chemother"},{"key":"10.1016\/j.cmi.2015.07.017_bib5","doi-asserted-by":"crossref","first-page":"1769","DOI":"10.1002\/hep.22549","article-title":"Naturally occurring dominant resistance mutations to hepatitis c virus protease and polymerase inhibitors in treatment-naive patients","volume":"48","author":"Kuntzen","year":"2008","journal-title":"Hepatology"},{"key":"10.1016\/j.cmi.2015.07.017_bib6","doi-asserted-by":"crossref","first-page":"2485","DOI":"10.1097\/QAD.0b013e328363b1f9","article-title":"Natural ns3 resistance polymorphisms occur frequently prior to treatment in hiv-positive patients with acute hepatitis c","volume":"27","author":"Leggewie","year":"2013","journal-title":"AIDS"},{"key":"10.1016\/j.cmi.2015.07.017_bib7","doi-asserted-by":"crossref","first-page":"149","DOI":"10.1016\/j.jcv.2014.06.023","article-title":"Patients eligible for treatment with simeprevir in a french center","volume":"61","author":"Morel","year":"2014","journal-title":"J Clin Virol: the official publication of the Pan American Society for Clinical Virology"},{"key":"10.1016\/j.cmi.2015.07.017_bib8","doi-asserted-by":"crossref","first-page":"10","DOI":"10.1016\/j.antiviral.2015.01.003","article-title":"Prevalence of the hepatitis c virus ns3 polymorphism q80k in genotype 1 patients in the european region","volume":"116C","author":"Sarrazin","year":"2015","journal-title":"Antiviral Res"},{"key":"10.1016\/j.cmi.2015.07.017_bib9","doi-asserted-by":"crossref","first-page":"984","DOI":"10.1093\/jac\/dkr581","article-title":"Naturally occurring hepatitis c virus (hcv) ns3\/4a protease inhibitor resistance-related mutations in hcv genotype 1-infected subjects in Italy","volume":"67","author":"Vicenti","year":"2012","journal-title":"J Antimicrob Chemother"},{"key":"10.1016\/j.cmi.2015.07.017_bib10","doi-asserted-by":"crossref","first-page":"6079","DOI":"10.1128\/AAC.03466-14","article-title":"Hepatitis c virus (hcv) ns3 sequence diversity and antiviral resistance-associated variant frequency in hcv\/hiv coinfection","volume":"58","author":"Jabara","year":"2014","journal-title":"Antimicrob Agents Chemother"},{"key":"10.1016\/j.cmi.2015.07.017_bib11","doi-asserted-by":"crossref","first-page":"1878","DOI":"10.1128\/AAC.01452-09","article-title":"In vitro resistance profile of the hepatitis c virus ns3\/4a protease inhibitor tmc435","volume":"54","author":"Lenz","year":"2010","journal-title":"Antimicrob Agents Chemother"},{"key":"10.1016\/j.cmi.2015.07.017_bib12","doi-asserted-by":"crossref","first-page":"1669","DOI":"10.1053\/j.gastro.2014.02.051","article-title":"Simeprevir with peginterferon and ribavirin leads to high rates of svr in patients with hcv genotype 1 who relapsed after previous therapy: A phase 3 trial","volume":"146","author":"Forns","year":"2014","journal-title":"Gastroenterology"},{"key":"10.1016\/j.cmi.2015.07.017_bib13","doi-asserted-by":"crossref","first-page":"403","DOI":"10.1016\/S0140-6736(14)60494-3","article-title":"Simeprevir with pegylated interferon alfa 2a plus ribavirin in treatment-naive patients with chronic hepatitis c virus genotype 1 infection (quest-1): A phase 3, randomised, double-blind, placebo-controlled trial","volume":"384","author":"Jacobson","year":"2014","journal-title":"Lancet"},{"key":"10.1016\/j.cmi.2015.07.017_bib14","doi-asserted-by":"crossref","first-page":"414","DOI":"10.1016\/S0140-6736(14)60538-9","article-title":"Simeprevir with pegylated interferon alfa 2a or 2b plus ribavirin in treatment-naive patients with chronic hepatitis c virus genotype 1 infection (quest-2): a randomised, double-blind, placebo-controlled phase 3 trial","volume":"384","author":"Manns","year":"2014","journal-title":"Lancet"},{"key":"10.1016\/j.cmi.2015.07.017_bib15","unstructured":"Simeprevir summary of product characteristics. Available at: http:\/\/www.Ema.Europa.Eu\/docs\/en_gb\/document_library\/epar_-_product_information\/human\/002777\/wc500167867.Pdf [accessed 3.03.15]."},{"key":"10.1016\/j.cmi.2015.07.017_bib16","doi-asserted-by":"crossref","first-page":"10","DOI":"10.14806\/ej.17.1.200","article-title":"Cutadapt removes adapter sequences from high-throughput sequencing reads","volume":"17","author":"Martin","year":"2011","journal-title":"EMBnet J"},{"key":"10.1016\/j.cmi.2015.07.017_bib17","doi-asserted-by":"crossref","first-page":"94","DOI":"10.1093\/bioinformatics\/btu587","article-title":"Virvarseq: A low-frequency virus variant detection pipeline for illumina sequencing using adaptive base-calling accuracy filtering","volume":"31","author":"Verbist","year":"2015","journal-title":"Bioinformatics"},{"key":"10.1016\/j.cmi.2015.07.017_bib18","doi-asserted-by":"crossref","first-page":"1871","DOI":"10.1093\/infdis\/jiu340","article-title":"Deep-sequencing analysis of the gene encoding the hepatitis c virus nonstructural 3-4a protease confirms a low prevalence of telaprevir-resistant variants at baseline and the end of the realize study","volume":"210","author":"Dierynck","year":"2014","journal-title":"J Infect Dis"},{"key":"10.1016\/j.cmi.2015.07.017_bib19","doi-asserted-by":"crossref","first-page":"54","DOI":"10.1016\/j.virusres.2012.03.002","article-title":"Assessment of phylogenetic sensitivity for reconstructing hiv-1 epidemiological relationships","volume":"166","author":"Beloukas","year":"2012","journal-title":"Virus Res"},{"key":"10.1016\/j.cmi.2015.07.017_bib20","doi-asserted-by":"crossref","first-page":"307","DOI":"10.1093\/sysbio\/syq010","article-title":"New algorithms and methods to estimate maximum-likelihood phylogenies: assessing the performance of phyml 3.0","volume":"59","author":"Guindon","year":"2010","journal-title":"Syst Biol"},{"key":"10.1016\/j.cmi.2015.07.017_bib21","doi-asserted-by":"crossref","first-page":"e9490","DOI":"10.1371\/journal.pone.0009490","article-title":"Fasttree 2--approximately maximum-likelihood trees for large alignments","volume":"5","author":"Price","year":"2010","journal-title":"PloS One"},{"key":"10.1016\/j.cmi.2015.07.017_bib22","doi-asserted-by":"crossref","first-page":"8359","DOI":"10.1128\/JVI.02582-10","article-title":"Detection of minority resistance during early hiv-1 infection: natural variation and spurious detection rather than transmission and evolution of multiple viral variants","volume":"85","author":"Gianella","year":"2011","journal-title":"J Virol"},{"key":"10.1016\/j.cmi.2015.07.017_bib23","doi-asserted-by":"crossref","first-page":"1288","DOI":"10.1093\/infdis\/jiu613","article-title":"Global origin and transmission of hepatitis c virus nonstructural protein 3 q80k polymorphism","volume":"211","author":"McCloskey","year":"2015","journal-title":"J Infect Dis"},{"key":"10.1016\/j.cmi.2015.07.017_bib24","doi-asserted-by":"crossref","first-page":"608","DOI":"10.1111\/j.1365-2893.2010.01342.x","article-title":"Evidence for separation of hcv subtype 1a into two distinct clades","volume":"18","author":"Pickett","year":"2011","journal-title":"J Viral Hepat"},{"key":"10.1016\/j.cmi.2015.07.017_bib25","doi-asserted-by":"crossref","first-page":"1756","DOI":"10.1016\/S0140-6736(14)61036-9","article-title":"Simeprevir plus sofosbuvir, with or without ribavirin, to treat chronic infection with hepatitis c virus genotype 1 in non-responders to pegylated interferon and ribavirin and treatment-naive patients: the cosmos randomised study","volume":"384","author":"Lawitz","year":"2014","journal-title":"Lancet"},{"key":"10.1016\/j.cmi.2015.07.017_bib26","doi-asserted-by":"crossref","first-page":"3670","DOI":"10.1128\/AAC.00308-12","article-title":"Resistance analysis of the hepatitis c virus ns3 protease inhibitor asunaprevir","volume":"56","author":"McPhee","year":"2012","journal-title":"Antimicrob Agents Chemother"},{"key":"10.1016\/j.cmi.2015.07.017_bib27","doi-asserted-by":"crossref","first-page":"988","DOI":"10.1128\/AAC.04227-14","article-title":"In vitro and in vivo antiviral activity and resistance profile of the hepatitis c virus ns3\/4a protease inhibitor abt-450","volume":"59","author":"Pilot-Matias","year":"2015","journal-title":"Antimicrob Agents Chemother"},{"key":"10.1016\/j.cmi.2015.07.017_bib28","doi-asserted-by":"crossref","first-page":"1008","DOI":"10.1016\/j.jhep.2014.11.032","article-title":"Virology analyses of hcv isolates from genotype 1-infected patients treated with simeprevir plus peginterferon\/ribavirin in phase iib\/iii studies","volume":"62","author":"Lenz","year":"2015","journal-title":"J Hepatol"},{"key":"10.1016\/j.cmi.2015.07.017_bib29","doi-asserted-by":"crossref","first-page":"1314","DOI":"10.1002\/jmv.23966","article-title":"Evolution of simeprevir-resistant variants over time by ultra-deep sequencing in hcv genotype 1b","volume":"86","author":"Akuta","year":"2014","journal-title":"J Med Virol"}],"container-title":["Clinical Microbiology and Infection"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S1198743X1500734X?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S1198743X1500734X?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2018,9,20]],"date-time":"2018-09-20T15:24:38Z","timestamp":1537457078000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S1198743X1500734X"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2015,11]]},"references-count":29,"journal-issue":{"issue":"11","published-print":{"date-parts":[[2015,11]]}},"alternative-id":["S1198743X1500734X"],"URL":"https:\/\/doi.org\/10.1016\/j.cmi.2015.07.017","relation":{},"ISSN":["1198-743X"],"issn-type":[{"value":"1198-743X","type":"print"}],"subject":[],"published":{"date-parts":[[2015,11]]}}}